Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-SU, insulin secretagogues].

M Kikuchi1

  • 1Institute for Adult Diseases, Asahi Life Foundation.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 13, 1999
PubMed
Summary

Three novel oral hypoglycemic agents (NN-623, A-4166, KAD-1229) show promise for type 2 diabetes. These non-sulfonylurea secretagogues are safe and effective for early-stage NIDDM treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human lung cancer cell line producing hepatocyte growth factor/scatter factor.

Japanese journal of cancer research : Gann·1992
Same author

Non-lysosomal degradation of misfolded human lysozymes with and without an asparagine-linked glycosylation site.

European journal of biochemistry·1992
Same author

Chromosome abnormalities in liposarcomas.

Cancer genetics and cytogenetics·1992
Same author

Are plasma endotoxin levels related to burn size and prognosis?

Burns : journal of the International Society for Burn Injuries·1992
Same author

Nonsense mutation of glucokinase gene in late-onset non-insulin-dependent diabetes mellitus.

Lancet (London, England)·1992
Same author

Malignant histiocytosis in a patient with chronic active Epstein-Barr virus infection.

Lancet (London, England)·1992

Area of Science:

  • Pharmacology
  • Endocrinology
  • Diabetes Mellitus

Background:

  • Overview of novel oral hypoglycemic agents NN-623, A-4166, and KAD-1229.
  • These agents are non-sulfonylurea (non-SU) insulin secretagogues.
  • Comparison with traditional sulfonylureas regarding action and pharmacokinetics.

Purpose of the Study:

  • To overview the chemical structures, mechanisms of action, bioavailabilities, and clinical effects of NN-623, A-4166, and KAD-1229.
  • To evaluate their insulinotropic and hypoglycemic actions.
  • To assess their safety and efficacy in clinical trials for NIDDM.

Main Methods:

  • Review of chemical structures and pharmacokinetic data (absorption and excretion rates).
  • Analysis of mechanisms involving SU-receptors and K-ATP channels.
  • Evaluation of clinical trial data on efficacy and safety in NIDDM patients.

Main Results:

  • NN-623, A-4166, and KAD-1229 demonstrate rapid absorption (Tmax < 30 min) and excretion (T 1/2 < 60 min).
  • They stimulate the initial phase of insulin release, reducing postprandial glucose spikes.
  • Clinical trials confirm efficacy and safety in non-insulin-dependent diabetes mellitus (NIDDM) subjects.

Conclusions:

  • These novel agents are effective and safe for managing NIDDM.
  • Their rapid pharmacokinetic profiles lead to quicker, shorter hypoglycemic effects than sulfonylureas.
  • Recommended as a first-line treatment for early-stage NIDDM.

Related Experiment Videos